This was partially supported in tumor-bearing lean mice treated with IFNγ neutralizing antibody, as Gp100+ melanoma cells from these mice had lower surface expression of MHC-I and MHC-II but unexpectedly showed no difference in the frequencies of Gp100+ cells compared to control mice (Supplementary Fig. S7). The gene discussed is PMEL; the disease is neoplasm.